Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Triple-negative breast cancer Stories

2012-03-24 03:35:37

Study presented Friday at 65th annual meeting of Society of Surgical Oncology Could blocking a testosterone receptor lead to a new way to treat an aggressive form of breast cancer? That's a question researchers at Mayo Clinic in Arizona and the Translational Genomics Research Institute (TGen) are exploring. Preliminary results of a Mayo Clinic - TGen collaborative study shows the testosterone receptor may be a potential target to attack in treating triple negative breast cancer (TNBC)....

2012-03-22 22:32:59

Scientists have uncovered a marker of DNA damage that could predict who will respond to platinum-based chemotherapy drugs like cisplatin or carboplatin. These drugs are widely used for ovarian cancer, but as with most cancer drugs, it can be difficult to predict who will respond to therapy. A team of researchers from the Dana-Farber Cancer Institute found that this marker, telomeric allelic imbalance or tAI, could predict sensitivity to therapy in patients with triple-negative breast...

2012-03-19 16:55:39

Putting the brakes on an abundant growth-promoting protein causes breast tumors to regress, according to a study published on March 19th in the Journal of Experimental Medicine. Triple-negative breast tumors lack all of the known growth receptors that serve as treatment targets in other types of breast cancer, making this the most clinically challenging subtype of the disease. Patients with these tumors tend to relapse earlier and have shorter disease-free survival. Andrei Goga and...

2012-03-16 09:40:43

A powerful new strategy for personalized anti-cancer therapy Researchers at the Kimmel Cancer Center at Jefferson have demonstrated for the first time that the metabolic biomarker MCT4 directly links clinical outcomes with a new model of tumor metabolism that has patients "feeding" their cancer cells. Their findings were published online March 15 in Cell Cycle. To validate the prognostic value of the biomarker, a research team led by Agnieszka K. Witkiewicz, M.D., Associate Professor of...

2012-03-14 21:14:04

A new study by University of Kentucky researchers provides insight into developing new treatment strategies for basal-like breast cancer, commonly known as triple-negative breast cancer. This cancer is associated with early metastasis and resistance to chemotherapy and occurs at women at a younger age. Tumor cells can exploit a cellular program that promotes cell migration and reduces adhesion between cells to spread to distant sites in the body. This cellular program, known as the...

2012-02-09 00:49:58

Similarities between genetic signatures in developing organs and breast cancer could predict and personalize cancer therapies Reviving a theory first proposed in the late 1800s that the development of organs in the normal embryo and the development of cancers are related, scientists at the Salk Institute for Biological Studies have studied organ development in mice to unravel how breast cancers, and perhaps other cancers, develop in people. Their findings provide new ways to predict and...

2012-01-11 07:30:00

SANTA CLARITA, Calif., Jan. 11, 2012 /PRNewswire/ -- The Princess Cruises Community Foundation and Susan G. Komen for the Cure® have announced a new three-year partnership for two research projects supporting the fight against breast cancer. One of the Foundation-supported research grants, at the University of California at Los Angeles (UCLA), will look at the molecular effects of the chemical BPA on breast cancer, while the other, at Stanford University School of Medicine,...

2011-12-12 10:35:43

Researchers at the Thomas Jefferson University Hospital and Kimmel Cancer Center at Jefferson have shown that loss of the retinoblastoma tumor suppressor gene (RB) in triple negative breast cancer patients is associated with better clinical outcomes. This is a new marker to identify the subset of these patients who may respond positively to chemotherapy. Today, no such marker is applied in care of triple negative breast cancer, and as a result, patients are all treated the same....

2011-12-09 06:30:00

QUEBEC CITY, Dec. 9, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced positive preclinical data in triple-negative breast cancer (TNBC) for its highly selective Erk 1/2 inhibitor anticancer compound, AEZS-131. Data showed that AEZS-131 selectively inhibits Erk at low nanomolar (nM) concentrations and induces G1 arrest. Accordingly, the cytotoxic effect of AEZS-131 was most pronounced in TNBC cell lines with mutations in the MAPK...

2011-12-08 23:28:02

Results presented at 2011 CTRC-AACR-San Antonio Breast Cancer Symposium Initial results from an ongoing clinical trial, the first designed to examine the utility of whole-genome sequencing for triple negative breast cancer, were reported today during the CRTC-AACR San Antonio Breast Cancer Symposium. The results indicate activation of targets not previously associated with triple negative disease and could point toward new treatment strategies. Based on mutations uncovered by...